StockData

Adlai Nortye vs Ensysce Biosciences

ANL and ENSC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ANL and ENSC compare

Ensysce Biosciences scores higher on the StockData Score (5 against 0 for Adlai Nortye), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricANLENSC
Size and price
Market cap–$7.5M
Share price$9.48$0.384
Change, 1 year508%−81.4%
Change, 5 years–−100.0%
Beta (5Y)3.903.77
Employees–8
StockData Score
Total score05 (better)
Valuation score01 (better)
Growth score01 (better)
Performance score00
Health score03 (better)
Dividend score00
Valuation
P/S–1.7×
Growth
Revenue growth (TTM)–−39.3%
Revenue growth, 5Y average–5.2%
Profitability
Operating margin−714%−281% (better)
Net margin−711%–
FCF margin−673%–
Financial health
Interest coverage−23.3× (better)−791.6×
Current ratio0.650.70 (better)
Altman Z-score–−81.05
Piotroski F-score1–
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions22.1%4.7%
Held by insiders14.7%6.2%
Insider net buying, 12 months−$411K$444K (better)
Short interest, % of float–0.49%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.